R&D
pharmaphorum podcast episode 93

Alzheimer’s drugs: An overview and update

When we covered JP Morgan in January, over and over we heard that neurodegenerative diseases, especially Alzheimer’s, were going to be one of the most exciting spaces in pharma this year.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

Patients
Anatomical graphic concept of a liver in 3D

Rewriting the MASLD playbook

Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.

R&D